Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Its pipeline products include ELS004, a pharmaceutical grade L-glutamine that is in Phase 1 clinical trial to treat diverticulosis. The company's preclinical stage products comprise ELS005 for the treatment of blood cancers; ELS003, a lab device/research tool to measure transmittance of cell sheet; and ELS002, a chondrocyte cell sheet technology to replace knee cartilage replacement or to treat osteoarthritis. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor (KM10544) for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers. The company was founded in 2000 and is headquartered in Torrance, California.